DCA Regulations
Subscribe to DCA Regulations mailing list to get updates to your email inbox or mailbox.
Together, protecting California consumers.
Learn More about DCA
News & Updates
CURES Reporting – New Law Effective January 1
Effective January 1, 2026, Assembly Bill (AB) 82 prohibits health care providers from reporting a prescription for or the dispensing of testosterone or mifepristone to the Controlled Substance Utilization and Evaluation System (CURES) or to the Department of Justice's contracted prescription data processing vendor, currently Bamboo Health. Existing records for testosterone or mifepristone will be removed from CURES on or before January 1, 2027. For more information about CURES, visit the Department of Justice's CURES webpage.
CURES Fee Increase
The Controlled Substance Utilization Review and Evaluation System (CURES) fee will increase from $9 to $15 annually for licenses expiring on and after July 1, 2025. Most affected license types will see a $30 CURES fee due to the biennial renewal cycle. For more information about CURES, visit the Department of Justice's CURES webpage.
News Release: Investigation Leads to Criminal Conviction, License Revocation
An investigation by the California Department of Consumer Affairs Division of Investigation on behalf of the Physical Therapy Board of California plays important role in criminal case and license revocation. Read the full press release.
Language & Americans with Disabilities Act Public Access
Additional Links
- Quarterly Licensing Data
- AB 2138 Data
- AB 2113
Expedited Licensure for Refugees, Asylees, and Holders of Special Immigrant Visas
